INMB Q4 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$163,000+1381.8% YoY

Gross Profit

$163,000100.0% margin

Operating Income

-$9M-5539.9% margin

Net Income

-$10M-5933.1% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+1064.3%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$100M

Total Liabilities

$20M

Stockholders' Equity

$80M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$163,000	$11,000	+1381.8%
Gross Profit	$163,000	$11,000	+1381.8%
Operating Income	-$9M	-$3M	-181.4%
Net Income	-$10M	-$3M	-201.8%